$ALNY

3 stories mentioning ALNYUpdated 39d ago

Every FINWIRES story that references ALNY, newest first.

Research Alert: CFRA Maintains Hold Opinion On Shares Of Alnylam Pharmaceuticals, Inc

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $319 from $340 based on our NPV analysis. We raise our 2026 EPS forecast to $9.32 from $8.02, and maintain our 2027 EPS estimate at $11.97. Alnylam (ALNY) reported a strong first quarter for 2026, exceeding both earnings and revenue estimates. The company achieved a significant milestone, in our view, surpassing $1B in quarterly product revenue for the first time in its history. This performance was largely due to the successful commercial launch and uptake of AMVUTTRA for ATTR-CM. While international TTR revenue grew 35% year-over-year in Q1, it declined by $7 million from the previous quarter. This was mainly due to a previously announced price adjustment in Germany following the ATTR-CM launch. We think a significant portion of ALNY's revenue is concentrated in its TTR franchise, which could be a vulnerability if new competitors or unforeseen challenges emerge.

$ALNY

Research49d ago

Research Alert: Alny Posts Record Q1 Sales Driven By Ttr Franchise And Solid Pipeline Progress

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Alnylam delivered exceptional Q1 2026 results, achieving a historic milestone of over $1B in quarterly product revenues for the first time in its 23-year history. The company reported non-GAAP EPS of $2.05 vs. $0.29 in the prior year, significantly ahead of the $1.47 consensus, while total revenues reached $1,167M (+96% Y/Y), driven by outstanding net product revenue performance of $1,036M (+121% Y/Y). The TTR franchise continued its remarkable growth trajectory, generating $910M (+153% Y/Y), with AMVUTTRA contributing $890M (+187% Y/Y) as the therapy maintained exceptional commercial momentum one year after its U.S. launch for ATTR-CM. The company reiterated its 2026 financial guidance, projecting total net product revenues of $4.9B-$5.3B and TTR net product revenues of $4.4B-$4.7B. Management highlighted significant pipeline progress, including faster-than-anticipated enrollment in the TRITON-CM Phase 3 study of nucresiran, with multiple clinical readouts expected in 2H 2026.

$ALNY

Sectors49d ago

Sector Update: Health Care Stocks Rise Premarket Thursday

Health care stocks were rising premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1% higher and the iShares Biotechnology ETF (IBB) up 0.6%.Eli Lilly (LLY) shares were up more than 5% after the company reported higher Q1 non-GAAP earnings and revenue, and raised its 2026 outlook.Merck (MRK) stock was down more than 1% after the company said it swung to a Q1 adjusted loss.Alnylam Pharmaceuticals (ALNY) shares were up more than 2% after the company posted higher Q1 adjusted net income and revenue.

$ALNY$IBB$LLY$MRK$XLV

Track with the FINWIRES app suite

FolioX

Track ALNY in your portfolio

WheelAI

Analyze ALNY options with the wheel strategy

StockInsider

See market sentiment on ALNY